(NASDAQ: ANL) Adlai Nortye's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.27%.
Adlai Nortye's earnings in 2026 is -$22,529,000.On average, 7 Wall Street analysts forecast ANL's earnings for 2026 to be -$57,880,866, with the lowest ANL earnings forecast at -$123,064,459, and the highest ANL earnings forecast at -$32,456,561. On average, 6 Wall Street analysts forecast ANL's earnings for 2027 to be -$72,969,303, with the lowest ANL earnings forecast at -$121,171,160, and the highest ANL earnings forecast at -$50,713,376.
In 2028, ANL is forecast to generate -$104,981,518 in earnings, with the lowest earnings forecast at -$170,396,943 and the highest earnings forecast at -$58,827,516.